Fortress Biotech (NASDAQ:FBIO) CFO David Jin Acquires 15,000 Shares of Stock

Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CFO David Jin purchased 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were acquired at an average cost of $1.72 per share, with a total value of $25,800.00. Following the completion of the purchase, the chief financial officer directly owned 1,667,761 shares in the company, valued at $2,868,548.92. The trade was a 0.91% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

David Jin also recently made the following trade(s):

  • On Thursday, November 19th, David Jin acquired 7,605 shares of Fortress Biotech stock. The stock was acquired at an average cost of $1.87 per share, for a total transaction of $14,221.35.
  • On Wednesday, November 18th, David Jin acquired 25,000 shares of Fortress Biotech stock. The stock was acquired at an average cost of $1.91 per share, for a total transaction of $47,750.00.

Fortress Biotech Stock Performance

FBIO stock opened at $1.78 on Friday. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $2.07 and its two-hundred day simple moving average is $2.69. Fortress Biotech, Inc. has a twelve month low of $1.64 and a twelve month high of $4.53. The firm has a market cap of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last released its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. Analysts predict that Fortress Biotech, Inc. will post 2.66 earnings per share for the current year.

Institutional Trading of Fortress Biotech

A number of hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in Fortress Biotech during the 2nd quarter worth about $47,000. Renaissance Technologies LLC increased its position in Fortress Biotech by 22.8% during the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 18,490 shares during the period. Finally, Marshall Wace LLP purchased a new position in Fortress Biotech during the 3rd quarter valued at about $462,000. 96.51% of the stock is owned by hedge funds and other institutional investors.

Fortress Biotech News Summary

Here’s some of the latest news about FBIO:

  • Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares in transactions from November 17–19, investing about $340,000. The purchases increased both executives’ holdings and may signal confidence in the company, though insider buying alone does not establish a change in business outlook. CEO filing CFO filing
  • Neutral Sentiment: Zacks initiated coverage with a “hold” rating, offering no clear bullish or bearish signal. Zacks ratings
  • Neutral Sentiment: HC Wainwright estimates earnings per share of $2.66 for FY2026, in line with consensus, and $2.37 for FY2027. The lower projected figure for 2027 may temper optimism, but these are analyst estimates rather than company guidance. HC Wainwright estimate coverage

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FBIO. Wall Street Zen lowered shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings downgraded shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Finally, Zacks Research assumed coverage on shares of Fortress Biotech in a research report on Wednesday. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.00.

Read Our Latest Report on FBIO

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Recommended Stories

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.